Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin plus bendamustine and rituximab in BTK inhibitor–relapsed mantle cell lymphoma
2021-000468-32Phase 2Completed
- Sponsor
- Kooperativní lymfomová skupina
- Start
- Jun 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin in mantle cell lymphoma (MCL), sponsored by Kooperativní lymfomová skupina. Primary endpoint: Progression-free survival. Started Jun 2021; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2021-000468-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000468-32.